Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

JenaValve's Trilogy valve wins first FDA approval for severe aortic regurgitation treatment
Medical device, cardiovascular, transcatheter aortic valve replacement, aortic regurgitation, minimally invasive surgery - Read more

Johnson & Johnson's Icotyde (icotrokinra) wins FDA approval for moderate-to-severe plaque psoriasis targeting interleukin-23
Small molecule, autoimmune, psoriasis, IL-23 inhibitor, oral therapy - Read more

Samsung Bioepis, Sandoz partner on five next-generation biosimilars including SB36 vedolizumab biosimilar
Commercialization partnership, autoimmune, biosimilars, manufacturing agreement - Read more

Nautilus Biotechnology, Baylor College of Medicine partner on cancer proteomics research using Voyager Platform
Research collaboration, oncology, proteomics, single-molecule analysis - Read more

Elaris, Valneva partner on exclusive global license for C. difficile vaccine technology with milestone payments
Licensing deal, infectious disease, vaccine, milestone payments - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Aspen Neuroscience plans Ph3 trial for sasineprocel (ANPD001) cell therapy targeting Parkinson's disease following positive Ph1/2a data
Cell therapy, neurological, induced pluripotent stem cells, Parkinson's disease, dopaminergic neurons - Read more

Stoke Therapeutics reports Ph1/2 results for zorevunersen targeting SCN1A gene in Dravet syndrome treatment
Antisense oligonucleotide, neurological, Dravet syndrome, SCN1A gene, NaV1.1 protein - Read more

Sobi presents positive Ph2a results for Gamifant (emapalumab) targeting interferon-gamma in sepsis patients
Antibody, infectious disease, monoclonal antibody, sepsis, interferon-gamma target, precision medicine - Read more

Imperative Care nets $100M convertible financing, stroke treatment hardware developer
Neurological, medical devices, stroke treatment, robotic platform - Read more

Crossbow Therapeutics raises $77M Series B, developing next-generation cancer immunotherapies
Cancer, T cell engager, immunotherapy, clinical-stage - Read more

Excalipoint Therapeutics raises $68.7M seed, developing next-gen T cell cancer immunotherapies
Oncology, antibody, T cell engager, tri-specific antibody, clinical-stage, platform technology - Read more

Ovid Therapeutics raises $60M PIPE financing for brain disorder drug development
Neurological, small molecule, brain disorders, clinical-stage - Read more

Reviva Pharmaceuticals raises $10M public offering, late-stage CNS/inflammatory disease therapies
Central nervous system, late-stage, inflammatory, cardiometabolic - Read more

Kupando raises additional €10M ($11.5M) Series A for cancer, infectious disease therapies
Cancer, infectious disease, clinical-stage, platform technology - Read more

TerraPower commits $450M to build Philadelphia radioisotope production plant, boosting actinium-225 capacity 20-fold
Radioisotope, oncology, strategic, major transaction, operational - Read more

FDA releases draft guidance framework for drugmakers to replace animal testing with alternative methodologies
Drug development methodologies, regulatory, operational, strategic - Read more

Basecamp Research unveils Trillion Gene Atlas plan to sequence trillion proteins within two years
AI drug discovery, strategic, operational, major transaction - Read more [Paywall]

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

HSBC downgrades Eli Lilly stock citing obesity market pricing pressures and orforglipron competition concerns
GLP-1 agonist, obesity, financial, competitive, strategic - Read more

TrumpRx's "world's lowest" drug price claims challenged by NYT finding cheaper German prices
Small molecule, multiple therapeutic areas, cost reduction, competitive, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here